This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Stealth BioTherapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

14.4%

Tasa de crecimiento de los beneficios

62.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	-14.6%
Tasa de crecimiento de los ingresos	19.7%
Rentabilidad financiera	n/a
Margen neto	n/a
Última actualización de beneficios	31 Dec 2021

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero Stealth BioTherapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:S1BA Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 21	0	-53	20	27
30 Sep 21	0	-51	20	25
30 Jun 21	0	-56	20	24
31 Mar 21	0	-50	19	26
31 Dec 20	0	-57	19	29
30 Sep 20	21	-35	20	35
30 Jun 20	21	-41	22	38
31 Mar 20	21	-44	23	40
31 Dec 19	21	-72	22	45
30 Sep 19	0	-102	26	45
30 Jun 19	0	-108	25	51
31 Mar 19	0	-120	23	54
31 Dec 18	0	-97	22	53
30 Sep 18	0	-92	16	59
31 Dec 17	0	-83	17	63

Ingresos de calidad: S1BA is currently unprofitable.

Margen de beneficios creciente: S1BA is currently unprofitable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: S1BA is unprofitable, but has reduced losses over the past 5 years at a rate of 14.4% per year.

Acelerando crecimiento: Unable to compare S1BA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: S1BA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15%).

Rentabilidad financiera

Alta ROE: S1BA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

This company listing is no longer active

Stealth BioTherapeutics Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Stealth BioTherapeutics Corp to Report Q3, 2020 Results on Nov 05, 2020

Stealth BioTherapeutics Corp to Report Q2, 2020 Results on Aug 06, 2020

Recent updates

Stealth BioTherapeutics Corp(NasdaqGM:MITO) dropped from NASDAQ Composite Index

J. Wood Capital Advisors LLC and Morningside Venture (I) Investments Limited completed the acquisition of 22.5293% stake in Stealth BioTherapeutics Corp (NasdaqGM:MITO).

Less than half of directors are independent

Stealth BioTherapeutics Corp Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis

Stealth BioTherapeutics Corp Announces Departure of Robert Weiskopf as Chief Financial Officer

Stealth BioTherapeutics Announces Receipt of Non-Compliance Notice from Nasdaq

Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome

Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium

Stealth BioTherapeutics Corp Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide in Geographic Atrophy at the Clinical Trials at the Summit Meeting 2022

Stealth Biotherapeutics Announces Data from Reclaim-2 Phase 2 Trial of Elamipretide in Geographic Atrophy

Less than half of directors are independent

Stealth BioTherapeutics Corp Announces New SBT-272 Data and Trial Initiation

Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial

Stealth BioTherapeutics Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Requirement

Stealth BioTherapetuics Receives Nasdaq Notifications Regarding Minimum Bid and Market Value Requirements

Stealth Bio Therapeutics Provides Update on Clinical Stage Rare Disease Programs

Stealth BioTherapeutics Corp Presents Positive Elamipretide Data in Pediatric Cardiology At International Society for Heart Research North American Section Meeting 2021

Stealth BioTherapeutics Presents Positive SBT-272 Preclinical Data at International Parkinson and Movement Disorder Society Virtual Congress 2021

Stealth Biotherapeutics Strengthens IP Portfolio with Issuance of U.S. Patents Covering Elamipretide for Barth Syndrome

Stealth Biotherapeutics Corp Showcases Data for Elamipretide in Dry Age-Related Macular Degeneration At the 2021 Arvo Annual Meeting

Stealth BioTherapeutics Corp Announces Promotion of Marty Redmon to Chief Research & Development Officer

Stealth BioTherapeutics Corp Completes Enrollment of Phase 2 Study in Dry Age-Related Macular Degeneration with Geographic Atrophy

New 90-day high: €1.53

New 90-day high: €1.39

Stealth BioTherapeutics Granted Pre-NDA Meeting For Elamipretide As Treatment For Cardiomyopathy In Barth Syndrome

New 90-day high: €1.27

Stealth BioTherapeutics Corp Announces Board and Committee Changes

New 90-day low: €1.02

Revenue in line with expectations

New 90-day low: €1.03

Revenue in line with expectations

Stealth Biotherapeutics Announces Development Financing to Advance Elamipretide Clinical Trials

Stealth BioTherapeutics Corp to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €1.08

Stealth BioTherapeutics Announces Poster Presentation at 2020 Annual NEALS Meeting

New 90-day low - €1.21

New 90-day low - €1.46

Stealth BioTherapeutics Corp to Report Q2, 2020 Results on Aug 06, 2020

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado